PharmaLex enters Australia following acquisition of ERA Consulting
Brisbane-based ERA Consulting has joined PharmaLex, a 1,300-strong global professional services firm for the pharma, biotech and medtech industries.
The bolt-on of ERA Consulting provides Germany-headquartered PharmaLex with market entry in Australia, which it to data has been serving through affiliate partnerships and fly-in teams from Asia Pacific offices. Globally, PharmaLex now has 34 offices, most of which are across Europe.
Founded in 1994, PharmaLex advises and supports clients through the entire product lifecycle, from early strategic planning activities and non-clinical requirements to clinical development, regulatory submission processes and post-approval/maintenance post-launch activities.
ERA Consulting is a boutique consulting firm with circa 20 consultants that provides product development and regulatory support services, with a focus on the development of vaccines, advanced therapy medicinal products, and cell and gene therapies. The consultancy was founded in 1993 in Germany following a management buy-out of a regulatory function within a toxicology contract research organisation, and launched in Australia in 2004.
“Expanding our global network into Australia is an important step and will help us strengthen our Asia-Pacific reach,” said Thomas Dobmeyer, the chief executive officer of PharmaLex. “Australia is considered one of the strategic hubs for early clinical trials for biotechnology companies and is therefore a perfect location for a future expansion to Asia Pacific region.”
“ERA Consulting’s extensive expertise will add significant value to further build our biopharma solutions.”
Andrew Moore, the chief operating officer of ERA Consulting, said, “The ERA team is excited about becoming part of PharmaLex as this enables us to provide additional support to our clients through the breadth of their services and global presence.”
